26 J ournal of Medicinal Chemistry, 2000, Vol. 43, No. 1
Communications to the Editor
Samanen, J . M.; Smith, B. R.; Stadel, J .; Takata, D. T.; Vickery,
L.; Yuan, C. C. K.; Yue, T.-L. Discovery of an Imidazopyridine
Containing 1,4-Benzodiazepine Nonpeptide Vitronectin Receptor
Antagonist with Efficacy in a Restenosis Model. Bioorg. Med.
Chem. Lett. 1998, 8, 3171-3176.
(35) Lark, M. W.; Stroup, G. B.; Hwang, S.-M.; J ames, I. E.; Rieman,
D. J .; Drake, F. H.; Bradbeer, J .; Mathur, A.; Erhard, K. F.;
Newlander, K. A.; Ross, S. T.; Salyers, K. L.; Smith, B. R.; Miller,
W. H.; Huffman, W. F.; Gowen, M. Design and Characterization
of an Orally Active Arg-Gly-Asp Peptidomimetic Vitronectin
Receptor Antagonist, SB 265123, for the Prevention of Bone Loss
in Osteoporosis. J . Pharmacol. Exp. Ther. 1999, 291, 612-617.
(36) Binding affinity for human Rvâ3 was determined in a competi-
tive binding assay employing 3H-SK&F 107260 as the displaced
ligand. The Ki values represent the means of values determined
in two to three separate experiments; see: Wong, A.; Hwang, S.
M.; McDevitt, P.; McNulty, D.; Stadel, J . M.; J ohanson, K.
Studies on Rvâ3/Ligand Interactions Using a [3H]SK&F-107260
Binding Assay. Mol. Pharmacol. 1996, 50, 529-537.
(37) Binding affinity for human RIIbâ3 was determined in a competi-
tive binding assay employing 3H-SK&F 107260 as the displaced
ligand. The Ki values represent the means of values determined
in two to three separate experiments; see: Ali, F. E.; Bennett,
D. B.; Calvo, R. R.; Elliott, J . D.; Hwang, S.-M.; Ku, T. W.; Lago,
M. A.; Nichols, A. J .; Romoff, T. T.; Shah, D. H.; Vasko, J . A.;
Wong, A. S.; Yellin, T. O.; Yuan, C.-K.; Samanen, J . M.
Conformationally Constrained Peptides and Semipeptides De-
rived from RGD as Potent Inhibitors of the Platelet Fibrinogen
Receptor and Platelet Aggregation. J . Med. Chem. 1994, 37,
769-780.
(38) Affinity for human Rvâ3 in a cellular context was determined
by measuring the inhibition of the adhesion of purified human
vitronectin to HEK 293 cells transfected with human Rvâ3. The
IC50 values represent the means of values determined in two
experiments in triplicate with an internal standard; see: Kumar,
C. S.; J ames, I. E.; Wong, A.; Mwang, V.; Field, J . A.; Nuthu-
laganti, P.; Conner, J . R.; Eichman, C.; Ali, F.; Hwang, S. M.;
Rieman, D. J .; Drake, F. H.; Gowen, M. Cloning and Charac-
terization of a Novel Integrin â3 Subunit. J . Biol. Chem. 1997,
272, 16390-16397.
(39) Pharmacokinetic parameters were determined using noncom-
partmental analysis of plasma concentration of test compound
versus time data determined in two to three separate animals.
Oral bioavailability was calculated from the dose-normalized iv
and po AUC values, where AUC is the area under the plasma
concentration versus time curve; see: Gibaldi, M.; Perrier, D.
Absorption Kinetics and Bioavailability. In Pharmacokinetics,
2nd ed.; Swarbrick, J ., Ed.; Marcel Dekker: New York, 1982;
Vol. 15, pp 145-198.
(40) Antiaggregatory activity was assessed by measuring inhibition
of ADP-induced platelet aggregation in human platelet-rich
plasma; see: Samanen, J .; Ali, F. E.; Romoff, T.; Calvo, R.;
Sorenson, E.; Vasko, J .; Storer, B.; Berry, D.; Bennett, D.;
Strohsacker, M.; Powers, D.; Stadel, J .; Nichols, A. Development
of a Small RGD Peptide Fibrinogen Receptor Antagonist with
Potent Antiaggregatory Activity In Vitro. J . Med. Chem. 1991,
34, 3114-3125.
(41) Lark, M. W.; Stroup, G. B.; Cousins, R. D.; J ames, I. E.; Hwang,
S. M.; Bradbeer, J .; Hoffman, S.; Lechowska, B.; Vasko-Moser,
J .; Zembryki, D.; Votta, B. J .; Lee-Rykaczewski, E.; Perng, D.;
Salyers, K.; Smith, B. R.; Liang, X.; Dodds, R. A.; Newlander,
K. A.; Ross, S. T.; Erhard, K. F.; Huffman, W. F.; Drake, F. H.;
Miller, W. H.; Gowen, M. An Orally Active Vitronectin Receptor
Rvâ3 Antagonist Prevents Bone Resorption In Vitro and In Vivo
in the Ovariectomized Rat. Bone 1998, 23, S219.
(42) Lark, M. W.; Stroup, G. B.; Dodds, R. A.; Kapadia, R.; Hwang,
S.; J ames, I. E.; Rieman, D. J .; Liang, X.; Ward, K.; Smith, B.
R. The Orally Active Vitronectin Receptor Antagonist, SB
273005, Prevents Trabecular Bone Loss in the Ovariectomized
(Ovx) Rat. J . Bone Miner. Res. 1999, 14, S482.
(43) J ames, I. E.; Lark, M. W.; Zembryki, D.; Lee-Rykaczewski, E.
V.; Hwang, S. M.; Tomaszek, T. A.; Belfiore, P.; Gowen, M.
Development and Characterization of a Human In Vitro Resorp-
tion Assay: Demonstration of Utility Using Novel Antiresorptive
Agents. J . Bone Miner. Res. 1999, 14, 1562-1569.
(22) Keenan, R. M.; Miller, W. H.; Barton, L. S.; Bondinell, W. E.;
Cousins, R. D.; Eppley, D. F.; Hwang, S.-M.; Kwon, C.; Lago,
M. A.; Nguyen, T. T.; Smith, B. R.; Uzinskas, I. N.; Yuan, C. C.
K. Nonpeptide Vitronectin Receptor Antagonists Containing
2-Aminopyridine Arginine Mimetics. Bioorg. Med. Chem. Lett.
1999, 9, 1801-1806.
(23) Miller, W. H.; Bondinell, W. E.; Cousins, R. D.; Erhard, K. F.;
J akas, D. R.; Keenan, R. M.; Ku, T. W.; Newlander, K. A.; Ross,
S. T.; Haltiwanger, R. C.; Bradbeer, J .; Drake, F. H.; Gowen,
M.; Hoffman, S. J .; Hwang, S.-M.; J ames, I. E.; Lark, M. W.;
Lechowska, B.; Rieman, D. J .; Stroup, G. B.; Vasko-Moser, J .
A.; Zembryki, D. L.; Azzarano, L. M.; Adams, P. C.; Salyers, K.
L.; Smith, B. R.; Ward, K. W.; J ohanson, K. O.; Huffman, W. F.
Highly Orally Bioavailable Nonpeptide Vitronectin Receptor
Antagonists with Efficacy in an Osteoporosis Model. Bioorg. Med.
Chem. Lett. 1999, 9, 1807-1812.
(24) Mousa, S. A.; Lorelli, W.; Mohamed, S.; Batt, D. G.; J adhav, P.
K.; Reilly, T. M. Rvâ3 Integrin Binding Affinity and Specificity
of SM256 in Various Species. J . Cardiovasc. Pharmacol. 1999,
33, 641-646.
(25) Rockwell, A. L.; Rafalski, M.; Pitts, W. J .; Batt, D. G.; Petraitis,
J . J .; DeGrado, W. F.; Mousa, S.; J adhav, P. K. Rapid Synthesis
of RGD Mimetics with Isoxazoline Scaffolds on Solid Phase:
Identification of Rvâ3 Antagonists Lead Compounds. Bioorg.
Med. Chem. Lett. 1999, 9, 937-942.
(26) Corbett, J . W.; Graciani, N. R.; Mousa, S. A.; DeGrado, W. F.
Solid-Phase Synthesis of a Selective Rvâ3 Integrin Antagonist
Library. Bioorg. Med. Chem. Lett. 1997, 7, 1371-1376.
(27) Nicolau, K. C.; Trujillo, J . I.; J andeleit, B.; Chibale, K.; Rosenfeld,
M.; Diefenbach, B.; Cheresh, D. A.; Goodman, S. L. Design,
Synthesis and Biological Evaluation of Nonpeptide Integrin
Antagonists. Bioorg. Med. Chem. 1998, 6, 1185-1208.
(28) Miller, W. H.; Newlander, K. A.; Eggleston, D. S.; Haltiwanger,
R. C. Synthesis of a 2-Benzazepine Analogue of a Potent,
Nonpeptide GPIIb/IIIa Antagonist. Tetrahedron Lett. 1995, 36,
373-376.
(29) Methyl (()-8-methoxy-3-oxo-2-(2,2,2-trifluoroethyl)-2,3,4,5-tet-
rahydro-2-benzazepine-4-acetate was resolved into its enanti-
omers by chiral HPLC using the following conditions: Daicel
Chiralcel OJ column (21.2 × 250 mm), methanol mobile phase,
15 mL/min flowrate, UV detection at 295 nm, 400 mg injection;
tR for methyl (R)-(+)-8-methoxy-3-oxo-2-(2,2,2-trifluoroethyl)-
2,3,4,5-tetrahydro-2-benzazepine-4-acetate ) 4.9 min; tR for
methyl (S)-(-)-8-methoxy-3-oxo-2-(2,2,2-trifluoroethyl)-2,3,4,5-
tetrahydro-2-benzazepine-4-acetate ) 6.6 min.
(30) Tables of crystal data, fractional atomic coordinates, anisotropic
thermal parameters for non-hydrogen atoms, and bond distances
and angles have been deposited with the Cambridge Crystal-
lographic Data Centre, Lensfield Road, Cambridge CB2 1EW,
United Kingdom. Listings of structure factors are available from
the authors upon request.
(31) Hughes, D. L. The Mitsunobu Reaction. Org. React. 1992, 42,
335-656.
(32) We have found through studies in a related series that the
N-oxide derivative 18 gave much better yields in the Mitsunobu
reaction that the corresponding free aminopyridine (R. D.
Cousins, unpublished results).
(33) 2-Aminopyridine derivatives have been reported as Arg mimetics
in the discovery of novel thrombin inhibitors; see: Misra, R. N.;
Kelly, Y. F.; Brown, B. R.; Roberts, D. G. M.; Chong, S.; Seiler,
S. M. Argatroban Analogues: Synthesis, Thrombin Inhibitory
Activity and Cell Permeability of Aminoheterocyclic Guanidine
Surrogates. Bioorg. Med. Chem. Lett. 1994, 4, 2165-2170.
(34) Ward, K. W.; Azzarano, L. M.; Bondinell, W. E.; Cousins, R. D.;
Huffman, W. F.; J akas, D. R.; Keenan, R. M.; Ku, T. W.;
Lundberg, D.; Miller, W. H.; Mumaw, J . A.; Newlander, K. A.;
Pirhalla, J . L.; Roethke, T. J .; Salyers, K. L.; Souder, P. R.;
Stelman, G. J .; Smith, B. R. Preclinical Pharmacokinetics and
Interspecies Scaling of a Novel Vitronectin Receptor Antagonist.
Drug Metab. Dispos. 1999, 27, 1232-1241.
J M990446U